Drug Pricing Initiatives: Congress and stakeholders continue to discuss drug pricing reform measures, including those that were originally part of H.R. 5376 (the Build Back Better Act, or BBBA).

In a related development, the Federal Trade Commission (FTC) announced that it will “launch an inquiry into the prescription drug middleman industry, requiring the six largest pharmacy benefit managers [(PBMs)] to provide information and records regarding their business practices.” The FTC will “scrutinize the impact of vertically integrated [PBMs] on the access and affordability of prescription drugs.”